All In Biotech

NDA 217564 · Takeda Pharms USA

Fruzaqla

Fruquintinib · Oral

NovelPriority review

CDER novel approval, Nov 8, 2023: To treat refractory, metastatic colorectal cancer

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Nov 8, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

189

21 Phase 3, 47 recruiting

FAERS reports

3,941

3,790 serious, 1,270 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 31, 2026.

1. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. ( 1 )

Mechanism: Fruquintinib is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 with IC 50 values of 33, 35, and 0.5 nM, respectively. In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation. In vitro and in vivo studies showed fruquintinib inhibited VEGF-induced VEGFR-2 phosphorylation. In vivo studies showed fruquintinib inhibited tumor growth in a tumor xenograft mouse model of colon cancer.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 8, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
  • FRUZAQLA · FRUQUINTINIB 1MG · CAPSULE, ORAL · Prescription
  • FRUZAQLA · FRUQUINTINIB 5MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fruquintinib" as an intervention, any sponsor and status, largest first.

All 189 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death861
  • fatigue482
  • colorectal cancer metastatic396
  • colon cancer381
  • diarrhoea289
  • blood pressure increased272
  • decreased appetite249
  • asthenia246
  • myelosuppression244
  • dysphonia213
  • hypertension199
  • off label use190

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20196
202011
20215
202217
202359
20241,193
20251,820
2026830

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fruzaqla (Fruquintinib)

2024 spending

$137M

Beneficiaries

1,935

5,831 claims

Per beneficiary

$71,042

$935.61 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$4,562,634
2024$137,466,500

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.